HomeCompareKNBIF vs ARCC

KNBIF vs ARCC: Dividend Comparison 2026

KNBIF yields 9090.91% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KNBIF wins by $21569447714287804.00M in total portfolio value
10 years
KNBIF
KNBIF
● Live price
9090.91%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21569447714287804.00M
Annual income
$21,112,599,253,241,626,000,000.00
Full KNBIF calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — KNBIF vs ARCC

📍 KNBIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKNBIFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KNBIF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KNBIF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KNBIF
Annual income on $10K today (after 15% tax)
$772,727.27/yr
After 10yr DRIP, annual income (after tax)
$17,945,709,365,255,380,000,000.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, KNBIF beats the other by $17,945,709,365,255,380,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KNBIF + ARCC for your $10,000?

KNBIF: 50%ARCC: 50%
100% ARCC50/50100% KNBIF
Portfolio after 10yr
$10784723857143902.00M
Annual income
$10,556,299,626,620,813,000,000.00/yr
Blended yield
97.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

KNBIF
No analyst data
Altman Z
-21.3
Piotroski
2/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KNBIF buys
0
ARCC buys
0
No recent congressional trades found for KNBIF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKNBIFARCC
Forward yield9090.91%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$21569447714287804.00M$24.5K
Annual income after 10y$21,112,599,253,241,626,000,000.00$1.16
Total dividends collected$21538997001133020.00M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: KNBIF vs ARCC ($10,000, DRIP)

YearKNBIF PortfolioKNBIF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$919,791$909,090.91$11,381$541.15+$908.4KKNBIF
2$79,131,237$78,147,061.10$12,621$284.08+$79.12MKNBIF
3$6,367,969,272$6,283,298,848.49$13,827$145.31+$6367.96MKNBIF
4$479,373,708,687$472,559,981,565.83$15,062$73.43+$479373.69MKNBIF
5$33,759,466,880,937$33,246,537,012,641.96$16,364$36.89+$33759466.86MKNBIF
6$2,224,307,476,184,878$2,188,184,846,622,275.00$17,757$18.49+$2224307476.17MKNBIF
7$137,120,917,193,402,000$134,740,908,193,884,210.00$19,258$9.25+$137120917193.38MKNBIF
8$7,909,629,907,685,076,000$7,762,910,526,288,135,000.00$20,880$4.63+$7909629907685.06MKNBIF
9$426,961,178,547,826,460,000$418,497,874,546,603,460,000.00$22,636$2.32+$426961178547826.44MKNBIF
10$21,569,447,714,287,803,000,000$21,112,599,253,241,626,000,000.00$24,539$1.16+$21569447714287804.00MKNBIF

KNBIF vs ARCC: Complete Analysis 2026

KNBIFStock

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Full KNBIF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this KNBIF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KNBIF vs SCHDKNBIF vs JEPIKNBIF vs OKNBIF vs KOKNBIF vs MAINKNBIF vs HTGCKNBIF vs GBDCKNBIF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.